Education
About Us
Working with TipRanks
Follow Us
Prestige Consumer Healthcare (PBH)
NYSE:PBH
RESEARCH TOOLSreports
PBH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$62.35 - $90.04
Previous CloseN/A
Volume57.25K
Average Volume (3M)399.02K
Market Cap
$4.04B
Enterprise Value$4.88B
Total Cash (Recent Filing)$41.10M
Total Debt (Recent Filing)$324.14M
Price to Earnings (P/E)18.7
Beta0.43
Next Earnings
May 01, 2025EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.27
Shares Outstanding49,537,838
10 Day Avg. Volume464,895
30 Day Avg. Volume399,021
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.73
Price to Cash Flow (P/CF)16.00
P/FCF Ratio15.20
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.82
Enterprise Value/Ebitda13.70
Forecast
1Y Price Target
$99.00Price Target Upside24.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Prestige Consumer Healthcare News
PremiumCompany Announcements
Prestige Consumer Healthcare Reports Record Earnings Despite Challenges
PremiumCompany Announcements
Prestige Consumer Healthcare Reports Stable Earnings Growth---
Bulls Say, Bears Say
Bulls Say
Debt ManagementPrestige has significantly reduced its debt, offering flexibility for further debt reduction, share buybacks, or engaging in profitable acquisitions.
Market LeadershipTen of Prestige’s top 12 brands are market leaders in their respective segments, enhancing the company's competitive position.
Sales PerformancePBH reported strong results with sales beating guidance, driven by international and North American strength.
Bears Say
Supply Chain ChallengesManagement reiterated its FY25 guidance despite continued pressure from the Clear Eyes supply chain which shows its diversified portfolio is set up to perform in even tougher macro environments.
---
Ownership Overview
1.18% Insiders
41.59% Mutual Funds
22.79% Other Institutional Investors
6.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $62.35 and its highest was $90.04 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $4.04B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is May 01, 2025 which is in 21 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Feb 06, 2025. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.175 by $0.045.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare does not currently pay dividends.
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 1.3.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 49,537,838 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $1.22 in its last earnings report, beating expectations of $1.175. Following the earnings report the stock price went up 14.783%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
---
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$99.00 (24.01% Upside)
$99.00 (24.01% Upside)
Blogger Sentiment
Bullish
PBH Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 174.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.31%
12-Months-Change
Fundamentals
Return on Equity
12.63%
Trailing 12-Months
Asset Growth
-0.31%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
---
PBH Company Deck
---
PBH Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong quarterly performance with record sales and EPS, driven by international growth and improved financial health through debt reduction. However, challenges remain with declines in certain segments like Cough & Cold, supply chain constraints for Clear Eyes, and broader economic concerns such as tariffs and inflation.Read More>---
PBH Stock 12 Month Forecast
Average Price Target
$99.00
▲(24.01% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
Owens & Minor
―
Patterson Companies
―
Guardian Pharmacy Services, Inc. Class A
―
Best Analysts Covering PBH
1 Year
1 Year Success Rate
10/12 ratings generated profit
1 Year Average Return
+13.93%
reiterated a buy rating 2 months ago
Copying Susan Anderson's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +13.93% per trade.
---